21 – 30 of 247
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts.
2016) In Annals of the Rheumatic Diseases(
- Contribution to journal › Article
-
Mark
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
(
- Contribution to journal › Article
-
Mark
Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis
(
- Contribution to journal › Article
- 2015
-
Mark
PXK locus in systemic lupus erythematosus: fine mapping and functional analysis reveals novel susceptibility gene ABHD6
(
- Contribution to journal › Article
-
Mark
Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials
(
- Contribution to journal › Article
-
Mark
Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.
(
- Contribution to journal › Article
-
Mark
Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort
(
- Contribution to journal › Article
-
Mark
Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial
(
- Contribution to journal › Article
-
Mark
Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
(
- Contribution to journal › Article
-
Mark
The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
(
- Contribution to journal › Article